Barinthus Biotherapeutics plc.
BRNSBarinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Feb 15, 2026
7dMarket Overview
Stock performance and market intelligence
2 upcoming, 0 past
MVA-HBV Phase 2 Results Expected
Primary completion for MVA-HBV trial (NCT05343481) in Chronic Hepatitis B
SourceChAdOx1-HBV Phase 2 Results Expected
Primary completion for ChAdOx1-HBV trial (NCT05343481) in Chronic Hepatitis B
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
MVA-HBV
Chronic Hepatitis B
ChAdOx1-HBV
Hepatitis B
ChAdOx1-HPV
HPV Infection
MVA-NP+M1
Influenza
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
MVA-HBV | Phase 2 | Chronic Hepatitis B | - |
ChAdOx1-HBV | Phase 2 | Hepatitis B | - |
ChAdOx1-HPV | Phase 2 | HPV Infection | - |
MVA-NP+M1 | Phase 2 | Influenza | - |
Regulatory & News
Approvals, filings, and latest developments